EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Identification, validation, and characterization of approved and investigational drugs interfering with the SARS ‐ CoV ‐2 endoribonuclease Nsp15

Spyros D Chatziefthymiou iD, Maria Kuzikov iD, Sara Afandi, Greta Kovacs, Sukrit Srivastava, Andrea Zaliani iD, Andrey Gruzinov iD, Guillaume Pompidor iD, Michele Lunelli iD, Golam Rizvee Ahmed iD, Jörg Labahn, Johanna Hakanpää iD and 2 more

Protein Science · 2025

DOI: 10.1002/pro.70156 ↗

At a glance

Journal article in Protein Science, 2025. Written by Spyros D Chatziefthymiou and 13 co-authors. Institution: Photon Science, DESY, Hamburg, Germany. Major MEDLINE topics: SARS-CoV-2, Antiviral Agents, Endoribonucleases, Viral Nonstructural Proteins. Cited 5 times so far (Crossref); 78 references. The full text is freely available (open access, CC BY 4.0). Funded by: DESY Strategic Fund (DSF), HORIZON EUROPE Framework Programme.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Since the emergence of SARS‐CoV‐2 at the end of 2019, the virus has caused significant global health and economic disruptions. Despite the rapid development of antiviral vaccines and some approved treatments such as remdesivir and paxlovid, effective antiviral pharmacological treatments for COVID‐19 patients remain limited. This study explores Nsp15, a 3′‐uridylate‐specific RNA endonuclease, which has a critical role in immune system evasion and hence in escaping the innate immune sensors. We conducted a comprehensive drug repurposing screen and identified 44 compounds that showed more than 55% inhibition of Nsp15 activity in a real‐time fluorescence assay. A validation pipeline was employed to exclude unspecific interactions, and dose–response assays confirmed 29 compounds with an IC 50 below 10 μM. Structural studies, including molecular docking and x‐ray crystallography, revealed key interactions of identified inhibitors, such as TAS‐103 and YM‐155, with the Nsp15 active site and other critical regions. Our findings show that the identified compounds, particularly those retaining potency under different assay conditions, could serve as promising hits for developing Nsp15 inhibitors. Additionally, the study emphasizes the potential of combination therapies targeting multiple viral processes to enhance treatment efficacy and reduce the risk of drug resistance. This research contributes to the ongoing efforts to develop effective antiviral therapies for SARS‐CoV‐2 and possibly other coronaviruses.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2Antiviral AgentsEndoribonucleasesViral Nonstructural ProteinsCOVID-19 Drug TreatmentDrugs, InvestigationalHumansMolecular Docking SimulationDrug RepositioningCrystallography, X-Ray

Author keywords

SARS‐CoV‐2drug screeningmolecular dockingrepurposinguridine‐specific endoribonuclease Nsp15x‐ray crystal structure

Substances

Antiviral AgentsEndoribonucleasesViral Nonstructural Proteinsnidoviral uridylate-specific endoribonucleaseDrugs, Investigational

Authors and institutions

  • Photon Science, DESY, Hamburg, Germany.
  • Department for Structural Infection Biology, Centre for Structural Systems Biology (CSSB) & Helmholtz-Centre for Infection Research, Hamburg, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.
  • School of Science, Constructor University, Bremen, Germany.
  • Forschungszentrum Jülich, Institute of Complex Systems (ICS-6), Jülich, Germany.
  • Faculty of Mathematics, Informatics and Natural Sciences, Universität Hamburg, Hamburg, Germany.

ORCID profiles: Spyros D Chatziefthymiou, Maria Kuzikov, Andrea Zaliani, Andrey Gruzinov, Guillaume Pompidor, Michele Lunelli, Golam Rizvee Ahmed, Johanna Hakanpää, Björn Windshügel, Michael Kolbe

Funding

  • DESY Strategic Fund (DSF)
  • HORIZON EUROPE Framework Programme

Cite

APA

Chatziefthymiou, S. D., Kuzikov, M., Afandi, S., Kovacs, G., Srivastava, S., Zaliani, A., Gruzinov, A., Pompidor, G., Lunelli, M., Ahmed, G. R., Labahn, J., Hakanpää, J., Windshügel, B., & Kolbe, M. (2025). Identification, validation, and characterization of approved and investigational drugs interfering with the SARS ‐ CoV ‐2 endoribonuclease Nsp15. Protein Science. https://doi.org/10.1002/pro.70156

Vancouver

Chatziefthymiou SD, Kuzikov M, Afandi S, Kovacs G, Srivastava S, Zaliani A, et al. Identification, validation, and characterization of approved and investigational drugs interfering with the SARS ‐ CoV ‐2 endoribonuclease Nsp15. Protein Science. 2025. doi:10.1002/pro.70156

BibTeX
@article{Chatziefthymiou2025,
  author = {Chatziefthymiou, Spyros D and Kuzikov, Maria and Afandi, Sara and Kovacs, Greta and Srivastava, Sukrit and Zaliani, Andrea and Gruzinov, Andrey and Pompidor, Guillaume and Lunelli, Michele and Ahmed, Golam Rizvee and Labahn, Jörg and Hakanpää, Johanna and Windshügel, Björn and Kolbe, Michael},
  title = {Identification, validation, and characterization of approved and investigational drugs interfering with the SARS ‐ CoV ‐2 endoribonuclease Nsp15},
  journal = {Protein Science},
  year = {2025},
  doi = {10.1002/pro.70156}
}
Start for free →